Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • Dimethyloxalylglycine (DMOG) Product Overview

    2026-10-04

    Dimethyloxalylglycine (DMOG), also identified as DMOG and SKU A4506, is supplied by APExBIO as a research-use chemical. The product description characterizes it as a cell-permeable, competitive HIF prolyl hydroxylase inhibitor intended to support conceptual studies of hypoxia-inducible factor stabilization and the hypoxia signaling pathway.

    Documented conceptual scope

    According to the supplier description, DMOG is positioned for research involving oxygen sensing, hypoxia responses, transcriptional regulation, and inflammation and infection research. The same description references inflammation-related contexts, including an LPS-induced shock model, NF-κB pathway modulation, and immune regulation via IL-10 upregulation. These statements describe the product’s listed research scope rather than independently verified performance.

    Evidence boundaries

    No matched research paper was supplied for this overview. Accordingly, no independent conclusions can be made about efficacy, reproducibility, mechanism, cell- or model-specific suitability, or translational relevance. The product description should not be treated as a substitute for peer-reviewed evidence, and the listed scope should not be generalized across experimental systems or clinical settings.

    Applicability and limitations

    This overview is limited to documented product identity and the conceptual uses stated in the supplier material. It does not provide protocols, operating conditions, formulation guidance, or recommendations for experimental use. The product is described as intended for scientific research and not for diagnostic or medical purposes.